NCT05606614View on ClinicalTrials.gov

Safety and Efficacy of TSHA-102 in Adolescent and Adult Females With Rett Syndrome (REVEAL Adult Study)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

November 2, 2028

Study Completion Date

January 5, 2032

Conditions
Rett Syndrome
Interventions
GENETIC

TSHA-102

TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.

Trial Locations (6)

55101

NOT_YET_RECRUITING

Gillette Children's Hospital, Saint Paul

60612

RECRUITING

Rush University Medical Center, Chicago

75930

NOT_YET_RECRUITING

UT Southwestern Medical Center, Dallas

92093

RECRUITING

UC San Diego, La Jolla

02115

NOT_YET_RECRUITING

Boston Children's Hospital, Boston

Unknown

RECRUITING

CHU St. Justine, Montreal

All Listed Sponsors
lead

Taysha Gene Therapies, Inc.

INDUSTRY